Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from NYSE

3 Stocks Where Insiders Are Buying, Not Bailing

Heavy insider buying is showing up in overlooked stocks; discover what these purchases may signal about value and opportunity in 2026

MarketBeat · Jan 10

These 3 Underrated ETFs Could Boom in 2026

These three ETFs find unique approaches to popular themes and strategies and may be poised for a successful year in 2026.

MarketBeat · Jan 10

MarketBeat Week in Review – 01/05 - 01/09

Stocks had another good week despite a mixed jobs picture; investors will get the latest reading on inflation as another earnings season kicks off next week

MarketBeat · Jan 10

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Strong Dividend Growers for Income Without Rate Risk

Looking for income without utilities or REITs? These three dividend growers offer rising payouts, pricing power, and durable cash flow

MarketBeat · Jan 9

This ETF Is Up 146% as the Battle Over Rare Earths Heats Up

After being labeled a national security priority by the Trump administration, rare earths surged. That’s likely to continue this year amid ongoing tailwinds.

MarketBeat · Jan 9

5 Under-the-Radar Consumer Staples Stocks With Pricing Power

If you're looking for consumer staples with pricing power, these 5 under-the-radar stocks offer margin defense, earnings growth, dividends, and upside

MarketBeat · Jan 8

Albertsons: Deep Value on the Surface, Opportunity Beneath?

Albertsons is a deep-value opportunity for high-yield income investors in 2026, set up to rebound by 30% to 40% by year's end.

MarketBeat · Jan 8

Read news from The Economist, FT, and more,
with one subscription

Trump Just Sent Blackstone Stock Plunging Below Key Support Levels. How Should You Play BX Here?

Blackstone stock is in focus as Trump announces plans of banning institutional investors from buying residential properties. But does that warrant unloading BX shares today?

Barchart · Jan 8

NVIDIA’s Move Turns Archer Into More Than an eVTOL Bet

Archer Aviation combines a powerful new partnership with NVIDIA and an exceptionally liquid balance sheet to lead the race for electric aircraft certification.

MarketBeat · Jan 8

3 Stocks With Analyst Revisions That Could Drive Earnings Surprises

Analyst revisions often signal future earnings strength. Here are three stocks showing estimate momentum ahead of earnings

MarketBeat · Jan 8

Higher-for-Longer Rates Could Reward These 3 Overlooked Stocks

Higher interest rates may be a headwind for stocks in 2026; here are three stocks that can quietly benefit if rates stay higher for longer

MarketBeat · Jan 8

Crisis in the Caribbean: The Defense Sector Playbook

Demand is tilting to precision missiles and border surveillance, spotlighting RTX, LHX, and EMBJ stocks as arsenals refill and logistics tighten rapidly in 2026.

MarketBeat · Jan 7

3 Energy Plays to Watch as the Sector Reacts to New Developments

Energy stocks surged on Monday as markets reacted to renewed focus on Venezuela’s oil industry and U.S. policy direction.

MarketBeat · Jan 6

Why These 3 Mega-Caps Could Still Surprise Investors in 2026

Three durable compounders for 2026: Visa’s payment scale, Walmart’s 52-year dividend streak, and Amazon’s cloud-led rebound after a heavy AI spending cycle.

MarketBeat · Jan 6

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat · Jan 5

The S&P 500's Top-Performing Sectors: 3 Lead the Pack in 2025

The S&P 500 put up a strong performance in 2025. These sectors delivered the highest returns, all benefiting from the year's most prevalent investment theme.

MarketBeat · Jan 5

Notable Newcomers: These 2025 IPOs Dominated the Year

Karman, Circle Internet, and Hinge Health were IPO winners in 2025. Their strong growth helped drive performance, and analysts see shares going even higher.

MarketBeat · Jan 5

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

MarketBeat · Jan 5

3 Stocks Delivered +10% Buyback Yields in 2025—What's Next in 2026?

These three stocks delivered some of the highest buyback yields in the S&P 500 over the last 12 months. LUV's repurchases helped shares rise significantly.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat · Jan 5

These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever

With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.

MarketBeat · Jan 2

Duke Energy’s Nuclear Bet Signals the AI Power Shift

Duke Energy filed permit applications to build advanced nuclear reactors in North Carolina, signaling the start of a massive construction boom for the grid.

MarketBeat · Jan 2

D-Wave vs. IonQ vs. IBM vs. Google: Which Quantum Bets Will Win 2026?

Pure-play quantum companies may be attractive for their massive rallies in recent quarters, but some investors may find legacy tech names are a better fit.

MarketBeat · Jan 1

2026 Sector Playbook: 3 Sectors Trading Below Fair Value

If you're concerned about the valuation of AI stock, here are three undervalued sectors in which rotation may unlock value as rates shift lower

MarketBeat · Jan 1

From Rust to Riches: 2 Auto Parts Names Built for 2026

A record number of older vehicles on American roads ensures steady demand for aftermarket parts as drivers prioritize repairs over new car payments.

MarketBeat · Jan 1

Bullseye Bounce: Toms Capital Takes a Stake in Target

The entry of activist investor Toms Capital, coupled with a discounted valuation, signals strong potential for a turnaround for the retailer in the coming year.

MarketBeat · Dec 31, 2025

Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake

With activist investors gone and revenue stabilizing, the undervalued pharmaceutical giant offers a compelling chance for value investors in the coming year.

1 … 52 53 54 55

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations